Categories

What is Therapeutic Antibody Discovery and Why is it Important? Antibody therapeutics have tremendous research and clinical value having the potential to combat different diseases such as cancers, HIV, autoimmune, hereditary, and more. The technologies used to discover these antibody-based…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Pavel Ryzhov, Field Application Scientist Came aboard: April 2022 What do you do at Telesis Bio? I work with…

Since Köhler and Milstein first succeeded in fusing myeloma cell lines with B cells to create hybridomas in 1975,1 antibodies have become well-established therapeutics. With advantages relative to selectivity, effector function, and bioavailability over small molecule drugs, antibody therapeutics are…

Cellular therapy research is booming with applications in cancer and further innovations on the horizon for infectious, autoimmune, and chronic inflammatory diseases. The progression in understanding the tumor microenvironment and how the immune cells infiltrate and kill tumor cells has…

Laurence Warden, Senior Vice President, Engineering and Instrumentation, led his team to develop the BioXp® 9600 system – a high-throughput benchtop platform for synthetic biology workflows designed to empower scientists to accelerate the discovery of new vaccines and biologics. Read…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Silvio Cenzi, Senior Manager, Field Service Field Support Came aboard: January 10, 2022 What do you do at Telesis…

Ben Chiarelli, Founder and CEO of Cellibre, a company revolutionizing agricultural manufacturing, discussed the company’s goal of shortening their complex design-build-test process to produce globally significant products at scale. Ben also shared how the partnership with Telesis Bio empowered their…

We caught up with Jason Lehmann, Senior Product Marketing Manager at Telesis Bio, as he shares how our synthetic biology workstation, the BioXp® system, can accelerate your time to results by optimizing production workflows and overcoming synthesis bottlenecks. How do…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Ken Williams, Bioinformatics Scientist Lead Came aboard: February 2020 What do you do at Telesis Bio? I develop the…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Sydney Kerr, Senior Research Associate Came aboard: January 2021 What do you do at Telesis Bio? I work on…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Michelle Vargas, Scientist Came aboard: March 2021 What do you do at Telesis Bio? I work on the Research…

Built with Biology (Formerly SynBioBeta) hosted its global synthetic biology conference in Oakland, CA last week. The conference brought together synthetic biology’s leading community of innovators, investors, and thought leaders to collaborate in solving our world’s biggest problems through biology.…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: John Gill, Senior Director of Research and Development Came aboard: April 2020 What do you do at Telesis Bio?…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Elijah Grote, Software Engineer Came aboard: November 2020. What do you do at Telesis Bio? I add features and…

On Monday, January 24th, NBC 7 San Diego reporter Madison Weil interviewed Telesis Bio’s CEO, Todd Nelson, to discuss our recent early access collaboration and licensing agreement with Pfizer. Under this agreement, Pfizer gains early access to Telesis Bio’s proprietary…

We’re continuing our blog series, looking at the DNA of Telesis Bio — our incredible employees and their stories. Team member: Yanming Gong, Director of Synthesis Came aboard: September 2021. What do you do at Telesis Bio? I work in…

We’re proud of Telesis Bio’s Co-Founder and CTO, Dan Gibson, for being featured in this year’s Newsweek Magazine’s America’s Greatest Disruptor list. With his team of scientists at Telesis Bio, Dan Gibson is focused on creating a new paradigm for…

Telesis Bio’s mission is to drive innovation and apply breakthroughs in automation solutions for DNA, mRNA, and protein synthesis. These tools enable scientists to “write” biology for the betterment of the world, creating sustainable healthcare and technology solutions for humanity’s…

It’s been one year since we launched the BioXp® 3250 system — our fully automated biology for gene synthesis, cloning, mRNA synthesis, variant DNA libraries, and more — and we’re excited to see how much progress researchers have made with…

The Discovery on Target 2021 conference took place Sept 28-30 in Boston, bringing together several experts from across the US and globally to foster collaboration and share the latest advances in addressing key challenges in drug discovery. At this year’s…

Synthetic biology has become so important and widely used that it’s easy to forget how young the field is. Much of the innovation that we rely on today took place in just the last two decades. Telesis Bio was originally…

If you’re working with synthetic mRNA, we have exciting news to share. In addition to releasing a new workflow earlier this year that makes it possible to synthesize mRNA form pooled oligos in a single overnight run on our BioXp®…

RNA Day is on Sunday, August 1st this year, and we welcome the international celebration of one of the most versatile biomolecules we have seen come to life. We have seen RNA play a key role in addressing the COVID-19…

We’re celebrating two of the biggest discoveries in scientific history: The molecular structure of DNA and the complete mapping of all genes in the human genome The discovery of DNA’s double helix in 1953 and the completion of the Human…

The bacterial scourge of the citrus greening disease has affected citrus production worldwide, causing tree decline and a serious threat to Florida’s citrus industry. Citrus greening disease, or Huanglongbing (HLB), is caused by Candidotus liberibacter (CLass) and is spread by…

Scientists have made a new discovery that could eventually lead to more effective treatment for malaria. In a series of experiments that included using the BioXp® system, they determined that a key phospholipid and a related protein confer protection against…

Monoclonal antibodies represent an important class of therapies for an ever-increasing number of diseases, infections, and health conditions. That’s why scientists around the world are working to improve the processes required to engineer new antibody candidates for therapeutic use. The…

Since the start of the COVID-19 pandemic, the Telesis Bio team has been working hard to ensure that our customers have access to the tools they need to help in the fight against this public health scourge. We currently offer…

At a recent Oxford Global NextGen Omics UK congress, our own Kirsty Maclean gave a presentation about how the BioXp® system is powering advances in cell engineering. While she started with a high-level view of how synthetic biology applies to…

Back in 2013, I played a small role in response to what then seemed like the next potential pandemic — an outbreak of H7N9, an avian influenza virus. At the time, I was working with Novartis scientists, and we were…

In the age of COVID-19, there has been a ton of scientific interest in nanobodies, or single-domain antibodies that can be used for finely targeted viral vaccines. It’s also been a hot topic among users of our BioXp® system —…

Breast cancer is now recognized as the most common malignancy worldwide among women, irrespective of age. Today’s standard of care and breast cancer management relies heavily on chemotherapy, hormone therapy, and targeted therapy. However, there is still much to be…

The Telesis Bio team really enjoyed attending this year’s virtual Global Synthetic Biology Conference hosted by SynBioBeta. If you missed the event, we’ve got you covered — here’s our take on highlights from the meeting. BioXp® system in the spotlight…

For BioXp® system users, antibody drug discovery is one of the most popular applications. That’s why we were delighted to participate in the recent Oxford Global Biologics virtual conference, with a presentation from our own Kirsty Maclean, Director of Applications…

Several recent publications from the rockstar team at GigaGen illustrate how they are using the BioXp® system to streamline antibody drug discovery workflows. It’s tough to overstate the importance of this area of research: monoclonal antibodies, antibody drug conjugates, and…